Background: The incidence of thyroid cancer continues to rise all over the world. Thus, it is urgent to find a novel strategy for the treatment of thyroid cancer. Previous reports have confirmed that lncRNA CASC2 is involved in the pathogenesis of thyroid cancer. However, the mechanism by which CASC2 mediates the tumorigenesis of thyroid cancer remains unclear.
Methods: Gene and protein expressions in tissues or cells were detected by q-PCR and Western blot, respectively. Cell proliferation was tested by MTT assay. Flow cytometry was used to test cell apoptosis. Cell migration and invasion in thyroid cancer cells was detected by transwell assay. In addition, the correlation between CASC2 and miR-24-3p were investigated by Targetscan and dual-luciferase reporter assay. Finally, xenograft mice model was established to detect the effect of CASC2 on thyroid cancer .
Results: CASC2 was significantly downregulated in thyroid cancer. Overexpression of CASC2 inhibited the proliferation, migration, and invasion of thyroid cancer cells. In addition, upregulation of CASC2 could inhibit the tumorigenesis of TC via sponging miR-24-3p. Furthermore, overexpression of CASC2 significantly suppressed the growth of thyroid cancer .
Conclusion: Overexpression of CCASC2 inhibits the tumorigenesis of thyroid cancer and . Thus, CASC2 may serve as a novel target for the treatment of thyroid cancer.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7653600 | PMC |
Oncol Lett
March 2025
Department of Ultrasound, Affiliated Hospital of Guangdong Medical University, Zhanjiang, Guangdong 524002, P.R. China.
Primary squamous cell carcinoma of the thyroid (PSCCT) is a rare malignancy with a poor prognosis. Therefore, early diagnosis and treatment are critical to the survival of patients and to improve their quality of life. However, diagnosing this illness is challenging.
View Article and Find Full Text PDFJACC Case Rep
December 2024
Rutgers New Jersey Medical School, Newark, New Jersey, USA.
Anaplastic thyroid carcinoma (ATC) is a rare, yet extremely aggressive form of thyroid cancer characterized by rapid growth and early metastasis to distant sites. Cardiac involvement is very uncommon and the presentation of cardiac metastasis in ATC can vary widely, highlighting the importance of early clinical recognition. We describe an extremely rare case of metastatic ATC that spread to the right ventricle.
View Article and Find Full Text PDFCureus
December 2024
Department of Surgical Oncology, Shaukat Khanum Memorial Cancer Hospital and Research Centre, Lahore, PAK.
Introduction Thyroid malignancy remains a significant global health concern, making the accurate differentiation between benign and malignant thyroid nodules crucial for optimal patient management. Fine-needle aspiration cytology (FNAC) is the gold-standard preoperative diagnostic tool, and The Bethesda System for Reporting Thyroid Cytopathology provides a standardized framework for interpretation. This 10-year retrospective study evaluated the malignancy risk in surgically treated patients with thyroid nodules classified as Bethesda Category III by comparing FNAC findings with histopathological outcomes.
View Article and Find Full Text PDFCureus
December 2024
General Surgery, King Fahad Specialist Hospital, Buraydah, SAU.
Papillary thyroid cancer (PTC) is the most frequent thyroid malignancy. Recently, the incidence has become widespread among both male and female individuals worldwide. In this article, we aim to report a 32-year-old Saudi female who presented with a painless lateral neck mass for more than seven months, and on excisional biopsy, was found to have features of PTC.
View Article and Find Full Text PDFGland Surg
December 2024
Division of Endocrine and Oncologic Surgery, Department of Surgery, School of Medicine, Tulane University, New Orleans, LA, USA.
Background: With rising well-differentiated thyroid cancer (WDTC) incidence, the appropriate treatment choice remains controversial for T1 tumors <2 cm. This study analyzed differences in surgery refusal and survival outcomes between T1a (<1 cm) and T1b (1-2 cm) WDTC, examining the demographic and clinical characteristics associated with patients who decide to either undergo or refuse recommended surgery.
Methods: We studied 81,664 T1N0M0 WDTC patients in the Surveillance, Epidemiology, and End Results (SEER) registry [2000-2019].
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!